Long runs of homozygosity are associated with Alzheimer's disease
- PMID: 33627629
- PMCID: PMC7904832
- DOI: 10.1038/s41398-020-01145-1
Long runs of homozygosity are associated with Alzheimer's disease
Abstract
Long runs of homozygosity (ROH) are contiguous stretches of homozygous genotypes, which are a footprint of inbreeding and recessive inheritance. The presence of recessive loci is suggested for Alzheimer's disease (AD); however, their search has been poorly assessed to date. To investigate homozygosity in AD, here we performed a fine-scale ROH analysis using 10 independent cohorts of European ancestry (11,919 AD cases and 9181 controls.) We detected an increase of homozygosity in AD cases compared to controls [βAVROH (CI 95%) = 0.070 (0.037-0.104); P = 3.91 × 10-5; βFROH (CI95%) = 0.043 (0.009-0.076); P = 0.013]. ROHs increasing the risk of AD (OR > 1) were significantly overrepresented compared to ROHs increasing protection (p < 2.20 × 10-16). A significant ROH association with AD risk was detected upstream the HS3ST1 locus (chr4:11,189,482‒11,305,456), (β (CI 95%) = 1.09 (0.48 ‒ 1.48), p value = 9.03 × 10-4), previously related to AD. Next, to search for recessive candidate variants in ROHs, we constructed a homozygosity map of inbred AD cases extracted from an outbred population and explored ROH regions in whole-exome sequencing data (N = 1449). We detected a candidate marker, rs117458494, mapped in the SPON1 locus, which has been previously associated with amyloid metabolism. Here, we provide a research framework to look for recessive variants in AD using outbred populations. Our results showed that AD cases have enriched homozygosity, suggesting that recessive effects may explain a proportion of AD heritability.
Conflict of interest statement
The authors declare that they have no conflict of interest.
Figures



References
-
- 2019 Alzheimer’s disease facts and figures. Alzheimer’s Dement. 15, 321–387 (2019)
Publication types
MeSH terms
Grants and funding
- P30 AG066444/AG/NIA NIH HHS/United States
- R01 AG058501/AG/NIA NIH HHS/United States
- P50 AG016574/AG/NIA NIH HHS/United States
- R01 HL105756/HL/NHLBI NIH HHS/United States
- R01AG044546, P01AG003991, RF1AG053303, R01AG058501, U01AG058922, RF1AG058501 and R01AG057777/U.S. Department of Health & Human Services | National Institutes of Health (NIH)
- R01 AG032990/AG/NIA NIH HHS/United States
- R01 NS080820/NS/NINDS NIH HHS/United States
- P01 AG017216/AG/NIA NIH HHS/United States
- NIRG-11-200110, BAND-14-338165, AARG-16-441560 and BFG-15-362540/ALZ/Alzheimer's Association/United States
- U01 AG046152/AG/NIA NIH HHS/United States
- R01 AG057777/AG/NIA NIH HHS/United States
- U54 AG052427/AG/NIA NIH HHS/United States
- U01 AG058922/AG/NIA NIH HHS/United States
- R01 AG044546/AG/NIA NIH HHS/United States
- U24 AG021886/AG/NIA NIH HHS/United States
- U01 AG032984/AG/NIA NIH HHS/United States
- RF1 AG053303/AG/NIA NIH HHS/United States
- R01 AG030146/AG/NIA NIH HHS/United States
- U01 AG024904/AG/NIA NIH HHS/United States
- U01 AG016976/AG/NIA NIH HHS/United States
- P01 AG003991/AG/NIA NIH HHS/United States
- P50 AG005681/AG/NIA NIH HHS/United States
- U24 AG056270/AG/NIA NIH HHS/United States
- P01 AG026276/AG/NIA NIH HHS/United States
- R01 AG017917/AG/NIA NIH HHS/United States
- RF1 AG058501/AG/NIA NIH HHS/United States
- P30 AG010161/AG/NIA NIH HHS/United States
- R01 AG033193/AG/NIA NIH HHS/United States
- RF1 AG044546/AG/NIA NIH HHS/United States
- U01 AG046139/AG/NIA NIH HHS/United States
- P01 AG003949/AG/NIA NIH HHS/United States
- WT_/Wellcome Trust/United Kingdom
- P30 AG019610/AG/NIA NIH HHS/United States
- P50 AG025711/AG/NIA NIH HHS/United States
- R01 AG023193/AG/NIA NIH HHS/United States
- R01 AG018023/AG/NIA NIH HHS/United States
- U01 AG006786/AG/NIA NIH HHS/United States
- R01 AG036836/AG/NIA NIH HHS/United States
- R01 AG015819/AG/NIA NIH HHS/United States